GSK suspends dosing in Crohn's disease treatment trial

08/26/2013 | Reuters

GlaxoSmithKline said adverse events increased at a new higher dosage in a trial of vercirnon, an experimental treatment licensed from ChemoCentryx. The findings prompted GSK to suspend new patient recruitment and dosing pending further analysis in the Crohn's disease study. "The results from the SHIELD-1 study are clearly disappointing but we are committed to further explore the data to determine the way forward to help patients with this chronic debilitating gastrointestinal disease," a GSK official said.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX